Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18600696 | 0.83 | PTGS2 (0.39) | PTGS2SCN9A | |
| SCHEMBL19040387 | 0.78 | HTT (0.35) | PTGS2CYP3A4 | |
| SCHEMBL19040355 | 0.75 | TRPV4 (0.40) | PTGS2 | |
| SCHEMBL22532403 | 0.72 | TRPV4 (0.39) | PTGS2SCN9A | |
| SCHEMBL30719557 | 0.72 | TRPV4 (0.39) | PTGS2SCN9A | |
| SCHEMBL19040395 | 0.70 | ADORA3 (0.37) | — | |
| SCHEMBL29837679 | 0.69 | SCN9A (0.41) | SCN9ASCN5ACYP3A4CYP2C9 | |
| SCHEMBL26693685 | 0.69 | SCN9A (0.41) | SCN9ASCN5ACYP3A4CYP2C9 | |
| SCHEMBL18600866 | 0.65 | L3MBTL1 (0.38) | CYP3A4CYP2C9 | |
| SCHEMBL25226442 | 0.65 | APLNR (0.35) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180208587-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2018-07-26 | — | — | US | disclosed |
| US-9896441-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170183331-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183331-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | PTGS2 1029/4885SCN9A 1753/4885SCN5A 486/4885 |
| US-20180208587-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | PTGS2 1029/4885SCN9A 1753/4885SCN5A 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.